Research statistics

Cagrilintide research: publications and trials

What has been published on Cagrilintide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Cagrilintide works or is safe. For what it is and what the studies found, see the Cagrilintide profile.
Automated weekly refresh · data through November 8, 2026

At a glance

Publications, all years

96

Since 1986

Publications in 2026 so far

38

Through November 8, 2026

Human clinical research

20.0%

19 of 95 classified

Registered clinical trials

41

ClinicalTrials.gov

Randomized controlled trials

15

Publications reporting an RCT in people

Systematic reviews and meta-analyses

13

Preclinical studies

25.3%

12 animal · 11 in vitro · 1 computational

Records that only mention it

31

Not counted above

Status in the library: In clinical trials. Groups: Amylin analogues. 1 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Cagrilintide publications by year and evidence

1986, Preclinical (animal, in vitro, computational): 2 of 21987, Human clinical research: 1 of 61987, Preclinical (animal, in vitro, computational): 4 of 61987, Other and not yet classified: 1 of 61988, Preclinical (animal, in vitro, computational): 1 of 11990, Human clinical research: 1 of 11994, Human clinical research: 1 of 11995, Preclinical (animal, in vitro, computational): 1 of 12021, Human clinical research: 2 of 72021, Preclinical (animal, in vitro, computational): 1 of 72021, Reviews and meta-analyses: 2 of 72021, Other and not yet classified: 2 of 72022, Preclinical (animal, in vitro, computational): 1 of 32022, Reviews and meta-analyses: 2 of 32023, Human clinical research: 1 of 42023, Reviews and meta-analyses: 3 of 42024, Human clinical research: 1 of 102024, Preclinical (animal, in vitro, computational): 1 of 102024, Reviews and meta-analyses: 8 of 102025, Human clinical research: 3 of 222025, Preclinical (animal, in vitro, computational): 6 of 222025, Reviews and meta-analyses: 6 of 222025, Other and not yet classified: 7 of 222026 (to date), Human clinical research: 9 of 382026 (to date), Preclinical (animal, in vitro, computational): 7 of 382026 (to date), Reviews and meta-analyses: 20 of 382026 (to date), Other and not yet classified: 2 of 38Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0102030401986199020212026*
Counted PubMed publications by year of first publication. * 2026 runs to November 8, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
198602002
198714016
198801001
199010001
199410001
199501001
202121227
202201203
202310304
2024118010
2025366722
2026 (to date)9720238

Study types

Review28
Randomized controlled trial15
Animal study12
In vitro study11
Editorial, letter or other11
Meta-analysis9
Other clinical trial4
Systematic review4
Computational study1
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health56
Obesity and weight management49
Endocrinology25
Antimicrobial and infectious disease12
Cardiovascular8
Gastrointestinal7
Neurological and mental health4
Musculoskeletal3
Reproductive and sexual health2
Oncology1

Registered clinical trials

7 of 14 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 24 · Recruiting: 9 · Active, not recruiting: 7 · Not yet recruiting: 1
Phase 1: 17 · Phase 2: 4 · Phase 3: 20

TrialStatusPhaseStartedResults
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNCT07919405 · 1,408 enrolledNot yet recruitingPhase 32026-11—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · 80 enrolledRecruitingPhase 32026-08—
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504 · 285 enrolledRecruitingPhase 32026-08—
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 · 114 enrolledRecruitingPhase 12026-05—
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 · 50 enrolledCompletedPhase 12026-05—
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 · 234 enrolledRecruitingPhase 12026-05—
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 · 120 enrolledRecruitingPhase 12026-04—
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · 100 enrolledRecruitingPhase 12026-04—
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 · 100 enrolledRecruitingPhase 12026-02—
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · 460 enrolledRecruitingPhase 32026-01—
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · 300 enrolledActive, not recruitingPhase 32025-11—
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · 330 enrolledActive, not recruitingPhase 32025-11—
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 · 80 enrolledActive, not recruitingPhase 12025-09—
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 · 144 enrolledRecruitingPhase 12025-06—
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · 609 enrolledActive, not recruitingPhase 32025-06—
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · 400 enrolledActive, not recruitingPhase 32025-02—
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · 142 enrolledCompletedPhase 22025-01—
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 · 178 enrolledCompletedPhase 12024-12—
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 · 18 enrolledCompletedPhase 12024-12—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · 1,023 enrolledCompletedPhase 32024-11—
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 · 300 enrolledCompletedPhase 32024-06—
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · 270 enrolledCompletedPhase 22024-05—
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761 · 158 enrolledCompletedPhase 12024-05—
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · 626 enrolledCompletedPhase 22024-04—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · 274 enrolledCompletedPhase 32024-03—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 · 189 enrolledCompletedPhase 32024-03—
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · 34 enrolledCompletedPhase 12024-02—
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 · 62 enrolledCompletedPhase 12024-02—
A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092 · 164 enrolledCompletedPhase 12024-02—
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · 1,024 enrolledCompletedPhase 32024-01—
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 · 809 enrolledCompletedPhase 32023-11—
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · 2,734 enrolledCompletedPhase 32023-09—
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 · 300 enrolledCompletedPhase 32023-08—
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162 · 107 enrolledCompletedPhase 12023-04—
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104 · 32 enrolledCompletedPhase 12023-04—
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 · 331 enrolledCompletedPhase 32023-04—
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · 7,101 enrolledActive, not recruitingPhase 32023-03—
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · 1,200 enrolledCompletedPhase 32023-02—
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · 3,400 enrolledActive, not recruitingPhase 32022-11—
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 · 92 enrolledCompletedPhase 22021-08Posted
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078 · 40 enrolledCompletedPhase 12021-07—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

    Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times

    PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses

  2. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

    Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses

  3. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

    Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses

  4. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

    BMJ medicine · August 27, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42688617 · DOI 10.1136/bmjmed-2026-003026 · Reviews and meta-analyses

  5. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

    Annals of medicine and surgery (2012) · July 13, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42583410 · DOI 10.1097/ms9.0000000000005353 · Reviews and meta-analyses

  6. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

    Endocrinology, diabetes & metabolism · July 1, 2026 · Meta-analysis · cited 2 times · open access

    PMID 42207966 · DOI 10.1002/edm2.70248 · Reviews and meta-analyses

  7. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

    Diabetes, obesity & metabolism · March 16, 2026 · Meta-analysis · cited 5 times

    PMID 41834765 · DOI 10.1111/dom.70667 · Reviews and meta-analyses

  8. CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

    The American journal of cardiology · February 26, 2026 · Meta-analysis · cited 1 times

    PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030 · Reviews and meta-analyses

  9. Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.

    Obesity (Silver Spring, Md.) · November 4, 2025 · Meta-analysis · cited 2 times · open access

    PMID 41189318 · DOI 10.1002/oby.70054 · Reviews and meta-analyses

  10. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

    Lancet (London, England) · June 23, 2023 · Randomized controlled trial · cited 330 times · open access

    PMID 37364590 · DOI 10.1016/s0140-6736(23)01163-7 · Human clinical research

  2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

    Lancet (London, England) · April 22, 2021 · Randomized controlled trial · cited 315 times

    PMID 33894838 · DOI 10.1016/s0140-6736(21)00845-x · Human clinical research

  3. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

    Lancet (London, England) · November 16, 2021 · Randomized controlled trial · cited 273 times · open access

    PMID 34798060 · DOI 10.1016/s0140-6736(21)01751-7 · Human clinical research

  4. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

    The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 233 times

    PMID 40544433 · DOI 10.1056/nejmoa2502081 · Human clinical research

  5. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

    The New England journal of medicine · June 22, 2025 · Randomized controlled trial · cited 140 times

    PMID 40544432 · DOI 10.1056/nejmoa2502082 · Human clinical research

Latest publications

  1. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.

    Molecular metabolism · October 28, 2026 · Animal study · cited 0 times

    PMID 42951207 · DOI 10.1016/j.molmet.2026.102464 · Animal studies

  2. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

    Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times

    PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses

  3. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).

    American heart journal · October 6, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42838477 · DOI 10.1016/j.ahj.2026.107626 · Human clinical research

  4. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

    Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses

  5. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · October 1, 2026 · Review · cited 0 times · open access

    PMID 42808923 · DOI 10.1002/ncp.70180 · Reviews and meta-analyses

  6. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.

    Diabetes therapy : research, treatment and education of diabetes and related disorders · September 28, 2026 · Review · cited 0 times · open access

    PMID 42803913 · DOI 10.1007/s13300-026-01921-0 · Reviews and meta-analyses

  7. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

    Nature metabolism · September 15, 2026 · Animal study · cited 0 times · open access

    PMID 42744908 · DOI 10.1038/s42255-026-01603-y · Animal studies

  8. Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

    Diabetes, metabolic syndrome and obesity : targets and therapy · September 15, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42763732 · DOI 10.2147/dmso.s616418 · Reviews and meta-analyses

  9. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.

    Diabetes, metabolic syndrome and obesity : targets and therapy · September 2, 2026 · Review · cited 0 times · open access

    PMID 42812898 · DOI 10.2147/dmso.s626279 · Reviews and meta-analyses

  10. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

    Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times

    PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses

Browse all 96 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: AM833; Cagrilintide; NN9838

((TITLE_ABS:"AM833" OR CHEM:"AM833" OR TITLE_ABS:"AM 833" OR CHEM:"AM 833") OR (TITLE_ABS:"Cagrilintide" OR CHEM:"Cagrilintide") OR (TITLE_ABS:"NN9838" OR CHEM:"NN9838" OR TITLE_ABS:"NN 9838" OR CHEM:"NN 9838")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 9). Cagrilintide research statistics (Version weekly-2026-11-08) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cagrilintide